2,6-DMBQ suppresses cell proliferation and migration via inhibiting
mTOR/AKT and p38 MAPK signaling pathways in NSCLC cells
1. Introduction
Lung cancer is the most frequently diagnosed malignant cancer
and the leading cause of cancer mortality worldwide.1,2 The two
types of lung cancer are non-small cell lung cancer (NSCLC), which
comprises approximately 85% of lung cancer cases, and small cell
lung cancer (SCLC).3 Although clinical advances in prevention and
therapeutics against lung cancer have progressed in recent years,
the survival rate is still less than 20%.4 The poor survival of lung
cancer patients is due to chemoresistance and the distant metastasis at the time of diagnosis.5 Therefore, novel approaches to
chemotherapy, targeted therapy, and prevention of metastasis are
urgently needed.
Signaling pathways that regulate cell growth, cell survival,
genomic instability, and angiogenesis are correlated with lung
cancer progression and metastatic potential.6 V-Akt murine thymoma viral oncogene homolog (AKT) is a serine/threonine kinase
that regulates cell survival, proliferation and many other biological
responses through directly inducing the phosphorylation of
downstream substrates.7 AKT isoforms (AKT1, AKT2 and AKT3)
have a high sequence homology in the catalytic domains, but
diverge in the hydrophobic motif (HM) domain and the pleckstrin
homology (PH) domain.8 It was recently discovered that the AKT
signaling pathway induces epithelialemesenchymal transition
(EMT) and migration through regulating E-cadherin expression.9
Dual-treatment with EGFR and AKT inhibitors was found to synergistically inhibit tumor growth and promote apoptosis in EGFRresistant NSCLC models.10
1. Introduction
Lung cancer is the most frequently diagnosed malignant cancer
and the leading cause of cancer mortality worldwide.1,2 The two
types of lung cancer are non-small cell lung cancer (NSCLC), which
comprises approximately 85% of lung cancer cases, and small cell
lung cancer (SCLC).3 Although clinical advances in prevention and
therapeutics against lung cancer have progressed in recent years,
the survival rate is still less than 20%.4 The poor survival of lung
cancer patients is due to chemoresistance and the distant metastasis at the time of diagnosis.5 Therefore, novel approaches to
chemotherapy, targeted therapy, and prevention of metastasis are
urgently needed.
Signaling pathways that regulate cell growth, cell survival,
genomic instability, and angiogenesis are correlated with lung
cancer progression and metastatic potential.6 V-Akt murine thymoma viral oncogene homolog (AKT) is a serine/threonine kinase
that regulates cell survival, proliferation and many other biological
responses through directly inducing the phosphorylation of
downstream substrates.7 AKT isoforms (AKT1, AKT2 and AKT3)
have a high sequence homology in the catalytic domains, but
diverge in the hydrophobic motif (HM) domain and the pleckstrin
homology (PH) domain.8 It was recently discovered that the AKT
signaling pathway induces epithelialemesenchymal transition
(EMT) and migration through regulating E-cadherin expression.9
Dual-treatment with EGFR and AKT inhibitors was found to synergistically inhibit tumor growth and promote apoptosis in EGFRresistant NSCLC models.10
2. Materials and methods
2.1. Cell lines
H1299, H1650 and H358 human NSCLC cells were purchased
from the Cell Bank of the Chinese Academy of Sciences (Shanghai,
China). Cells were cytogenetically tested and authenticated before
generating cell stocks. Cells were cultured in RPMI 1640 medium
(Biological Industries, Cromwell, CT, USA) supplemented with 10%
FBS (Biological Industries) and 1% antibiotic-antimycotic solution
(Solarbio, Beijing, China). All cells were maintained at 37 C in a 5%
CO2 humidified incubator and cultured for a maximum of 8 weeks.
2.2. Reagents and antibodies
2,6-DMBQ was purchased from Shanghai Chemic Industry
(Shanghai, China). AKT-I, SB203580 (p38-I) and GSK3b-I were
purchased from MedChemExpress (Shanghai, China). Antibodies to
detect phosphorylated AKT (S473) (Cat# 4060, 1:1000), p38 MAPK
(T180/Y182) (Cat# 9211, 1:1000), MKK3/6 (S189/S207) (Cat# 12280,
1:1000), mTOR (S2481) (Cat# 2974, 1:1000), EGFR (Y1068) (Cat#
2220, 1:1000), GSK3b (S9) (Cat# 5558, 1:1000), -CDC2 (Cat# 9111,
1:1000), total AKT (Cat# 4691, 1:1000), GSK3b (Cat# 12456,
1:1000), -MKK3 (Cat# 8535, 1:1000), -mTOR (Cat# 2972, 1:1000),
-ERK1/2 (Cat# 4695, 1:1000), -JAK1 (Cat# 3344, 1:1000), -EGFR
(Cat# 2232, 1:1000), -CDC2 (Cat# 77055, 1:1000) and Cyclin B1
(Cat# 12231, 1:1000) were purchased from Cell Signaling Technology (Beverly, MA, USA). The b-actin (Cat# sc-47778, 1:3000) and
E-cadherin (Cat# sc-7870, 1:1000) antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phosphorylated
JAK1 (Y1022) (Cat# SAB4504446, 1:3000) was purchased from
SigmaeAldrich (St Louis, MO, USA). COX2 (Cat# ab15191, 1:1000)
was purchased from Abcam (Chembridge Science Park, Chembridge, UK). Phosphorylated ERK1/2 (T202/Y204) (Cat#700012,
1:1000) was purchased from Thermo Fisher Scientific (Waltham,
MA, USA). Goat anti-rabbit IgG (H þ L) (Cat# ZB2301, 1:10000) and
goat anti-mouse IgG (H þ L) (Cat# ZB2305, 1:10000) were purchased from Beijing Zhongshan Jinqiao Biotechnology Co. LTD
(Beijing, China).
2.3. Western blotting
Proteins were measured by BCA kit (Solarbio) following the
manufacturer's suggested protocol. Proteins were separated by
SDS-PAGE and transferred to polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ, USA). Membranes were then blocked with 5% nonfat dry milk (Solarbio) in
TBST (TBS with 1% Tween 20) at room temperature for 1 h. After
blocking, the membranes were washed three times with TBST
and incubated overnight with appropriate primary antibodies at
4 C. The next day, the membranes were washed with TBST three
times and then incubated with an appropriate horseradish
peroxidaseelinked secondary antibody for 1 h. The membranes
were washed three times with TBST and the immuno-reactive
proteins were detected by Thermo Scientific SuperSignal West
Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific) using the ImageQuant LA S4000 system (GE Healthcare,
Piscataway, NJ, USA).
2.4. Cell proliferation assay
Cells were seeded (2 103 cells per well) in 96-well plates
with 100 ml complete growth medium and incubated for 24 h at
37 C. Cells were treated with various concentrations of 2,6-
DMBQ diluted in 100 ml of complete growth medium for 48 h.
After the incubation period, 20 ml of MTT solution (Solarbio)
were added to each well and the cells were incubated for an
additional 2 h at 37 C. The cell culture medium was then discarded and replaced with 150 ml of DMSO (Kermel, Tianjin,
China). Formazan crystals were dissolved by gentle agitation.
Cell proliferation was measured at 570 nm wavelength using a
Thermo Multiskan plate-reader (Thermo Fisher Scientific, Waltham, MA, USA). To determine the IC50value of all compounds
used within this study, we chose the 72 h MTT result to calculate
the half maximal inhibitory concentration using GraphPad Prism
5 (GraphPad Software, San Diego, CA, USA). We used the calculated IC50 value of AKT-I or SB203580 or GSK3b-I for cotreatment with 2,6-DMBQ.
2.5. Anchorage-independent cell growth
Cells (8 103 per well) suspended in complete growth medium
-RPMI 1640 supplemented with 10% FBS and 10 mg/ml gentamycin
(Solarbio) were added to 0.3% agar (Becton, Dickinson and Company, NJ, USA) with or without various concentrations of 2,6-DMBQ
in a top layer over a base layer of 0.6% agar with or without various
concentrations of 2,6-DMBQ. The culture dishes were maintained
at 37 C in a 5% CO2 incubator for 2 weeks. Colonies were photographed using a wide-field microscope and processed for analysis
with the Image-Pro Plus software (v.6) program (Media Cybernetics, Rockville, MD, USA).
2.6. Colony formation assay
Cells were seeded (500 cells per well) in 6-well plates with 2 ml
complete growth medium (RPMI 1640 supplemented with 10% FBS
and 1% antibiotic-antimycotic solution) and incubated for 24 h.
Cells were treated with different concentrations of 2,6-DMBQ in
2 ml of complete growth medium and incubated for 1 week. Cells
were stained with 0.5% Coomassie brilliant blue (Solarbio) for
20 min and then imaged.
2.7. Cell cycle analysis
Cells were seeded (8 104 cells per dish) into 60 mm culture
dishes. After incubation for 24 h, cells were treated with various
concentrations of 2,6-DMBQ for 24 h and harvested. Cells were then
washed with cold phosphate buffered saline (PBS) and fixed in 1 ml
70% cold ethanol. After rehydration, cells were permeabilized with
0.6% Triton X-100 (Solarbio) and digested with 100 mg/ml RNase A
(Solarbio) for 1 h. Cells were subsequently stained with 20 mg/ml
propidium iodide (Clontech, Palo Alto, CA, USA) for 15 min before
analysis by flow cytometry (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA).
2.8. Wound healing assay
Cells were seeded (1 105 cells per well) in 6-well plates with
100 ml complete growth medium. After incubation for 24 h, the cells
were gently scratched using a plastic micro pipette tip and then
washed three times with PBS. Cells were treated with various
concentrations of 2,6-DMBQ for 24 h or 48 h. The 6-well plates
containing the scratch-wounds were photographed in three
different fields of each well. The average width of each scratchwounds was measured and calculated using ImageJ (National Institutes of Health, Bethesda, MD, USA).
2.9. Migration assay
The lower compartment of transwell chambers (Corning, Bedford, MA, USA) were coated with Matrigel (Becton, Dickinson and
Company, NJ, USA) and incubated for 30 min at room temperature
under sterile conditions. The lower compartment of each chamber
was then filled with 600 ml complete growth medium. Fifty thousand cells suspended in 200 ml complete growth medium with or
without 2,6-DMBQ were added to the upper compartment. The
chambers were incubated for 24 h at 37 C in a 5% CO2 atmosphere.
Migrated cells were fixed with methanol (Tianjin Zhiyuan Chemical
Reagent Co. LTD, Tianjin, China) and stained with hematoxylin
(Baso Diagnostics INC, Zhuhai, China) and eosin (Baso Diagnostics
INC) prior to imaging. Photos of the stained cells were analyzed
using the Image-Pro Plus software (v.6) program (Media
Cybernetics).
2.10. Statistical analysis
All quantitative results are indicated as mean values ± S.D.
Statistically significant differences were determined using the
Student's t test or by one-way ANOVA (p < 0.05). Statistical significance was determined using the Statistical Package for Social
Science (SPSS) 21.0 (Xishu software, Shanghai, China).
section_15
1.888.394.3394
1.307.218.9831
www.FWGERX.com
fwgerx@gmail.com
Sheridan Wyoming, USA
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
All sales final
avemar avemar success stories avemar supplement ave mar avemar cancer avemar pulvis avemar wheat germ extract avemar reviews avemar canada avemar dosage avemar for cancer avemar fermented wheat germ avemar cancer testimonials avemar for dogs fermented wheat germ extract canada fermented wheat germ for dogs avemar cancer treatment immunovet for dog sh-86 cancer treatment avemar side effects avemar tablets avemar where to buy what is avemar avemar fermented wheat germ extract fermented wheat germ extract how to make avemar avemar hungarydoes avemar really work fermented wheat germ extract cancer oncomar avemar film tabletta immunovet ave ultra fermented wheat germ buy avemar avemar ingredients fermented wheat germ wheat germ extract avemar tablete avemar uk aveultra cancer fwge h86 cancer treatment hidvegi immunovet review metatrol reviews metatrol vs avemar stevia america tracey yeend wheat germ extract afemarall natural cancer treatment alterna- tive cancer treatment canada alternative cancer treatments canada alternative cancer treatments in canada andrew hidvegi animal cancer care anti cancer supplements for dogs apoquel and cancer apoquel and lymphoma arveemar ashawaganda ashawaganda benefits avemar authentic canada authentic supplements authentic supplier authentic usaave ultraave promagneavechi tablets avemar australia avemar cena avemar forum avemar granulátum avemar granule avemar group avemar hu avemar kaufen avemar nz avemar prah avemar prospect avemar recenzie avemar skusenosti avemar.com avemar.huavemat avemr avemrmar avermar aveultra avexima tablets awge awemar awge awge com awge forum awge logo awge shop awge website